NASDAQ:VYNE

VYNE Therapeutics News Headlines

$3.63
+0.07 (+1.97 %)
(As of 05/7/2021 05:20 PM ET)
Add
Compare
Today's Range
$3.50
$3.75
50-Day Range
$4.52
$7.82
52-Week Range
$3.50
$13.20
Volume1.82 million shs
Average Volume1.99 million shs
Market Capitalization$186.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97

Headlines

VYNE Therapeutics (NASDAQ VYNE) News Headlines Today

SourceHeadline
FY2022 Earnings Estimate for VYNE Therapeutics Inc. Issued By Cantor Fitzgerald (NASDAQ:VYNE)FY2022 Earnings Estimate for VYNE Therapeutics Inc. Issued By Cantor Fitzgerald (NASDAQ:VYNE)
americanbankingnews.com - May 7 at 11:35 AM
VYNE Therapeutics (NASDAQ:VYNE) PT Lowered to $11.00 at HC WainwrightVYNE Therapeutics (NASDAQ:VYNE) PT Lowered to $11.00 at HC Wainwright
americanbankingnews.com - May 7 at 9:15 AM
VYNE Therapeutics Inc. (VYNE) Q1 2021 Earnings Call TranscriptVYNE Therapeutics Inc. (VYNE) Q1 2021 Earnings Call Transcript
fool.com - May 7 at 1:08 AM
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue EstimatesVYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
msn.com - May 6 at 11:42 AM
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateVYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 6 at 7:49 AM
VYNE Therapeutics Inc. (NASDAQ:VYNE) Receives Average Recommendation of "Buy" from BrokeragesVYNE Therapeutics Inc. (NASDAQ:VYNE) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - May 6 at 1:42 AM
VYNE Therapeutics (VYNE) Scheduled to Post Quarterly Earnings on ThursdayVYNE Therapeutics (VYNE) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - May 5 at 6:58 AM
VYNE Therapeutics earnings preview: what Wall Street is expectingVYNE Therapeutics earnings preview: what Wall Street is expecting
markets.businessinsider.com - May 4 at 5:45 PM
$5.08 Million in Sales Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter$5.08 Million in Sales Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter
americanbankingnews.com - May 2 at 2:54 AM
-$0.40 Earnings Per Share Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter-$0.40 Earnings Per Share Expected for VYNE Therapeutics Inc. (NASDAQ:VYNE) This Quarter
americanbankingnews.com - April 30 at 8:35 AM
VYNE Therapeutics (VYNE) to Release Quarterly Earnings on ThursdayVYNE Therapeutics (VYNE) to Release Quarterly Earnings on Thursday
americanbankingnews.com - April 29 at 8:52 AM
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
finance.yahoo.com - April 28 at 9:25 AM
VYNE Therapeutics(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year.VYNE Therapeutics'(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year.
finance.yahoo.com - April 22 at 3:00 PM
Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Quarterly Sales of $5.08 MillionZacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Quarterly Sales of $5.08 Million
americanbankingnews.com - April 15 at 1:56 AM
Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Earnings of -$0.40 Per ShareZacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Earnings of -$0.40 Per Share
americanbankingnews.com - April 13 at 10:42 AM
Outlook on the Acne Treatment Global Market to 2025 - Players Include Vyne Therapeutics, Bausch Health Companies and AbbvieOutlook on the Acne Treatment Global Market to 2025 - Players Include Vyne Therapeutics, Bausch Health Companies and Abbvie
finance.yahoo.com - March 30 at 8:05 AM
The Daily Biotech Pulse: Mercks Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity SpikesThe Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes
markets.businessinsider.com - March 17 at 7:59 AM
VYNE Therapeutics EPS beats by $0.08, misses on revenueVYNE Therapeutics EPS beats by $0.08, misses on revenue
seekingalpha.com - March 5 at 2:39 PM
VYNE Therapeutics to Present at Upcoming Virtual Investor ConferencesVYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
finance.yahoo.com - March 4 at 6:36 PM
VYNE Therapeutics Inc. (VYNE) Q4 2020 Earnings Call TranscriptVYNE Therapeutics Inc. (VYNE) Q4 2020 Earnings Call Transcript
fool.com - March 4 at 1:59 PM
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue EstimatesVYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates
msn.com - March 4 at 1:36 PM
VYNE Therapeutics Inc to Host Earnings CallVYNE Therapeutics Inc to Host Earnings Call
finance.yahoo.com - March 4 at 8:35 AM
VYNE Therapeutics to Present at the Cowen 41st Annual Health Care ConferenceVYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
finance.yahoo.com - March 1 at 5:34 PM
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic DermatitisVYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
finance.yahoo.com - March 1 at 10:10 AM
VYNE THERAPEUTICS -,0001 (26J.BE)VYNE THERAPEUTICS -,0001 (26J.BE)
ca.finance.yahoo.com - February 18 at 7:03 PM
What You Need To Know About The VYNE Therapeutics Inc. (NASDAQ:VYNE) Analyst Downgrade TodayWhat You Need To Know About The VYNE Therapeutics Inc. (NASDAQ:VYNE) Analyst Downgrade Today
finance.yahoo.com - February 17 at 8:05 AM
VYNE Therapeutics Announces Reverse Stock SplitVYNE Therapeutics Announces Reverse Stock Split
finance.yahoo.com - February 11 at 8:44 AM
Thinking about buying stock in Canopy Growth Corp, 3D Systems, Bilibili, Agenus, or Vyne Therapeutics?Thinking about buying stock in Canopy Growth Corp, 3D Systems, Bilibili, Agenus, or Vyne Therapeutics?
marketwatch.com - February 4 at 12:07 PM
VYNE Therapeutics Announces FDA Approval of AMZEEQ(R) (Minocycline) Label UpdateVYNE Therapeutics Announces FDA Approval of AMZEEQ(R) (Minocycline) Label Update
marketwatch.com - February 2 at 12:34 PM
Why Vir Biotech, Concert Pharma And More Are Moving TodayWhy Vir Biotech, Concert Pharma And More Are Moving Today
markets.businessinsider.com - February 1 at 12:48 PM
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label UpdateVYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
finance.yahoo.com - February 1 at 9:15 AM
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate UpdateVYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
finance.yahoo.com - January 29 at 12:45 PM
Can Vyne Therapeutics Stock Keep Soaring?Can Vyne Therapeutics Stock Keep Soaring?
nasdaq.com - January 28 at 9:56 AM
VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesVYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
finance.yahoo.com - January 26 at 9:23 AM
ROCE Insights For VYNE TherapeuticsROCE Insights For VYNE Therapeutics
benzinga.com - January 25 at 1:36 PM
VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) CompanyVYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company
finance.yahoo.com - January 21 at 9:14 AM
VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this WeekVYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week
finance.yahoo.com - January 5 at 8:26 AM
VYNE Therapeutics Inc. (NASDAQ:VYNE): Are Analysts Optimistic?VYNE Therapeutics Inc. (NASDAQ:VYNE): Are Analysts Optimistic?
finance.yahoo.com - December 24 at 12:56 PM
VYNE Therapeutics IncVYNE Therapeutics Inc
bloomberg.com - December 19 at 11:04 PM
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in AcneVYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
finance.yahoo.com - December 17 at 9:47 AM
VYNE Therapeutics Added to Nasdaq Biotechnology IndexVYNE Therapeutics Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 16 at 12:33 PM
VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%
finance.yahoo.com - December 15 at 10:12 AM
Is VYNE A Good Stock To Buy Now?Is VYNE A Good Stock To Buy Now?
finance.yahoo.com - December 9 at 11:13 PM
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic DermatologyVYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
finance.yahoo.com - December 1 at 1:13 PM
VYNE Therapeutics (VYNE) CEO David Domzalski on Q3 2020 Results - Earnings Call TranscriptVYNE Therapeutics (VYNE) CEO David Domzalski on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 3:27 PM
US$7.07 - Thats What Analysts Think VYNE Therapeutics Inc. (NASDAQ:VYNE) Is Worth After These ResultsUS$7.07 - That's What Analysts Think VYNE Therapeutics Inc. (NASDAQ:VYNE) Is Worth After These Results
finance.yahoo.com - November 9 at 1:50 PM
Foamix Pharmaceuticals Ltd (FOMX) CEO David Domzalski on Q3 2020 Results - Earnings Call TranscriptFoamix Pharmaceuticals Ltd (FOMX) CEO David Domzalski on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 1:05 PM
VYNE Therapeutics EPS beats by $0.02, beats on revenueVYNE Therapeutics EPS beats by $0.02, beats on revenue
seekingalpha.com - November 5 at 8:31 AM
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5thVYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
finance.yahoo.com - October 28 at 8:42 AM
VYNE Therapeutics Zilxi foam added to Express Scripts coverageVYNE Therapeutics' Zilxi foam added to Express Scripts coverage
seekingalpha.com - October 7 at 2:03 PM
This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.